ProfileGDS5678 / 1447930_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 83% 90% 90% 93% 88% 85% 88% 88% 88% 87% 89% 90% 88% 89% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.0974983
GSM967853U87-EV human glioblastoma xenograft - Control 27.2083890
GSM967854U87-EV human glioblastoma xenograft - Control 37.2512990
GSM967855U87-EV human glioblastoma xenograft - Control 48.0584993
GSM967856U87-EV human glioblastoma xenograft - Control 56.9325188
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.2056785
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.6493288
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.8101688
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.8237988
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.8057787
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 27.0468189
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 37.2303990
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.8697288
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.9872689